Evaluation of current survival and prognostic factors in multiple myeloma: Staging ISS or R-ISS?
Abstract views: 29
/ 
PDF downloads: 15
DOI:
https://doi.org/10.26900/hsq.2605Keywords:
Multiple myeloma, ISS, R-ISS, LDH, RDWAbstract
Multiple myeloma (MM) is a complex hematological malignancy, and understanding the factors influencing prognosis and survival is crucial for improving patient outcomes. This study aims to evaluate the factors influencing the prognosis and survival of MM patients by comparing the International Staging System (ISS) with the Revised ISS (R-ISS). MM patients treated and followed up between 2015 and 2023 were retrospectively analyzed. According to ISS staging, 21.4% of patients were categorized as Stage 1, 30% as Stage 2, and 48.6% as Stage 3. Similarly, the R-ISS system revealed 14.3% as Stage 1, while 42.9% were Stage 2, and 42.9% were Stage 3. These findings indicate that the two systems provide differing stage distributions, which could impact prognosis evaluation. Mortality occurred in 58.6% of patients during the follow-up period, highlighting the severity of the disease in later stages. Further analysis revealed that higher levels of red cell distribution width (RDW), phosphorus content, lactate dehydrogenase (LDH), and beta-2 microglobulin levels were significantly associated with mortality, emphasizing their potential as markers of poor prognosis. In particular, ISS Stage II and III, R-ISS Stage III, along with elevated RDW, total protein, phosphorus, and LDH, were identified as independent prognostic factors. These results suggest that while both staging systems offer valuable insights, specific biomarkers play a crucial role in refining prognostic accuracy. In conclusion, while the ISS system appears to provide more meaningful staging information in this cohort compared to R-ISS, integrating additional biomarkers like RDW and LDH could enhance the prediction of patient outcomes.
Downloads
References
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma. JAMA. 2022;327(5):464-77. doi: 10.1001/jama.2022.0003.
Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, staging, and myeloma. Med Sci. 2021;9(1):3. doi: 10.3390/medsci9010003.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
Multiple Myeloma,National Diagnosis and Treatment Guide. Turkish Hematology Association.; 2020.
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management. Am J Hematol. 2020;95(5):548-67. doi: 10.1002/ajh.25791.
Soliman AM, Das S, Teoh SL. Next-generation biomarkers in multiple myeloma: understanding the molecular basis for potential use in diagnosis and prognosis. Int J Mol Sci. 2021;22(14):7470. doi: 10.3390/ijms22147470.
Durie BGM, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U.
Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20. doi: 10.1200/JCO.2005.04.242.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.
D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a european myeloma network (EMN) report within the HARMONY project. J Clin Oncol. 2022;40(29):3406-18. doi: 10.1200/JCO.21.02614.
Bębnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, et al. Immunological prognostic factors in multiple myeloma. Int J Mol Sci. 2021;22(7):3587. doi: 10.3390/ijms22073587.
Intzes S, Symeonidou M, Zagoridis K, Pentidou A, Emmanouil S. Socioeconomic status is globally a prognostic factor for overall survival of multiple myeloma patients; synthesis of studies and review of the literature. Mediterr J Hematol Infect Dis. 2020;13(1):e2021006. doi: 10.4084/mjhid.2021.006.
Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications. Cells. 2021;10(2):336. doi: 10.3390/cells10020336.
Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73. doi: 10.1038/sj.leu.2404284.
Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599-605. doi: 10.1200/JCO.2009.25.2114.
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK. SEER Cancer Statistics Review 1975–2016; National Cancer Institute: Bethesda, MD, USA.; 2019.
Matsue K, Matsue Y, Fujisawa M, Fukumoto K, Suehara Y, Sugihara H, et al. Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents. Leuk Lymphoma. 2016;57(1):110-5. doi: 10.3109/10428194.2015.1041386.
Du C, Li L, Fan H, Mao X, Liu J, Xu Y, et al. The age-dependent changes in risk weights of the prognostic factors for multiple myeloma. Hematology. 2023;28(1):2258686. doi: 10.1080/16078454.2023.2258686.
Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G, et al. Sex differences in multiple myeloma biology but not clinical outcomes: results from 3894 patients in the myeloma XI trial. Clin Lymphoma Myeloma Leuk. 2021;21(10):667-75. doi: 10.1016/j.clml.2021.04.013.
Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, et al. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous haematopoietic stem cell transplant. Br J Haematol. 2023;201(4):e37-e41. doi: 10.1111/bjh.18753.
Bangolo AI, Fwelo P, Trivedi C, Sagireddy S, Aljanaahi H, Auda A, et al. Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades. World J Clin Oncol. 2023;14(4):179-89. doi: 10.5306/wjco.v14.i4.179.
Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The diagnosis and treatment of multiple myeloma. Dtsch Arztebl Int. 2016;113(27-28):470-6. doi: 10.3238/arztebl.2016.0470.
Mohty M, Cavo M, Fink L, Gonzalez‐McQuire S, Leleu H, Mateos M, et al. Understanding mortality in multiple myeloma: findings of a european retrospective chart review. Eur J Haematol. 2019;103(2):107-15. doi: 10.1111/ejh.13264.
Andriandi, Kamal AF. Survival rate of multiple myeloma patients in Indonesia: A retrospective study in multiple myeloma at a single institution. Ann Med Surg. 2019;41:11-15. doi: 10.1016/j.amsu.2019.03.011.
Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ B. 2016;(36):e418-e23. doi: 10.1200/EDBK_159009.
Gopalakrishnan S, D’Souza A, Scott E, Fraser R, Davila O, Shah N, et al. Revised international staging system is predictive and prognostic for early relapse (<24 months) after autologous transplantation for newly diagnosed multiple myeloma. Biol Blood Marrow Transplant. 2019;25(4):683-8. doi: 10.1016/j.bbmt.2018.12.141.
Grant SJ, Wildes TM, Rosko AE, Silberstein J, Giri S. A real‐world data analysis of predictors of early mortality after a diagnosis of multiple myeloma. Cancer. 2023;129(13):2023-34. doi: 10.1002/cncr.34760.
Bila J, Jelicic J, Dencic Fekete M, Trajkovic G, Sretenovic A, Perunicic Jovanovic M, et al. The revised international staging system compared to the classical international staging system better discriminates risk groups among transplant-ineligible multiple myeloma patients. Oncol Res Treat. 2017;40(10):616-20. doi: 10.1159/000478935.
Schavgoulidze A, Lauwers-Cances V, Perrot A, Avet-Loiseau H, Corre J. The discriminatory ability of the R-ISS is equivalent to the ISS in a large cohort of newly diagnosed multiple myeloma (NDMM) patients. Blood. 2020;136(1):46-7. doi: 10.1182/blood-2020-136996.
Talarico M, Manicardi M, Vitolo M, Malavasi VL, Valenti AC, Sgreccia D, et al. Red cell distribution width and patient outcome in cardiovascular disease: a real-world’’ analysis. J Cardiovasc Dev Dis. 2021;8(10):120. doi: 10.3390/jcdd8100120.
Lee H, Kong SY, Sohn JY, Shim H, Youn HS, Lee S, et al. Elevated red clood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma. Biomed Res Int. 2014;2014:145619. doi: 10.1155/2014/145619.
Zhou D, Xu P, Peng M, Shao X, Wang M, Ouyang J, et al. Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. Clin Chim Acta. 2018;481:34-41. doi: 10.1016/j.cca.2018.02.009.
Gavriatopoulou M, Terpos E, Kastritis E, Dimopoulos MA. Current treatments for renal failure due to multiple myeloma. Expert Opin Pharmacother. 2016;17(16):2165-77. doi: 10.1080/14656566.2016.1236915.
Kang MG, Won EJ, Choi HW, Kim HR, Choi HJ, Park HR, et al. Serum parathyroid hormone is a new potential risk factor in multiple myeloma. Biomed Res Int. 2014;2014:804182. doi: 10.1155/2014/804182.
Qian J, Jin J, Luo H, Jin C, Wang L, Qian W, et al. Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases. Hematology. 2017;22(8):472-6. doi: 10.1080/10245332.2017.1309493.
Gu Y, Yuan YH, Xu J, Shi QL, Qu XY, Guo R, et al. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. Oncotarget. 2017;8(29):48350-61. doi: 10.18632/oncotarget.16237.
Pfahler V, D’Anastasi M, Dürr H, Schinner R, Ricke J, Baur‐Melnyk A. Tumor load in patients with multiple myeloma: β₂‐microglobulin levels versus low‐dose whole‐body CT. Eur J Haematol. 2020;104(5):383-9. doi: 10.1111/ejh.13356.
Hofbauer D, Mougiakakos D, Broggini L, Zaiss M, Büttner-Herold M, Bach C, et al. β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. Immunity. 2021;54(8):1772-87. doi: 10.1016/j.immuni.2021.07.002.
Ortega F, González M, Moro MJ, Gascón A, Duarte I, Martín M, et al. Prognostic effect of beta 2-microglobulin in multiple myeloma. Med Clin (Barc). 1992;99(17):645-8.
Petra Dorina, Oltean G, Demian Smaranda, Candea Marcela MI. Beta-2 microglobulin as prognostic marker in multiple myeloma. Acta Medica Marisiensis. 2011;57:229-32.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Holistence Publications
This work is licensed under a Creative Commons Attribution 4.0 International License.
When the article is accepted for publication in the HSQ authors transfer all copyright in the article to the Holistence Academy Ar-Ge Yazılım Yayıncılık Eğitim Danışmanlık ve Organizasyon Ticaret Ltd. Şti.The authors reserve all proprietary right other than copyright, such as patent rights.
Everyone who is listed as an author in this article should have made a substantial, direct, intellectual contribution to the work and should take public responsibility for it.
This paper contains works that have not previously published or not under consideration for publication in other journals.
